Intermediate Doses of LMWH Appear Safe in Older COVID-19 Patients

Pharmacy Technician

PTCB Recertification and State Required CE

START NOW

Pharmacist

Pharmacists Library

All the CE you need for 1 year to meet state requirements just $97.00.

START NOW
oatph

Intermediate Doses of LMWH Appear Safe in Older COVID-19 Patients

Emerging research suggests that anticoagulation therapy is associated with better outcomes in some patients with severe COVID-19 patients. But what about those who are older or who have co-morbidities and are at higher risk of bleeding? Find out what Italian researchers determined when they looked at the effect of intermediate doses of low molecular weight heparin.

PESARO, ITALY – One emerging issue in treatment of coronavirus disease-19 (COVID-19) is the importance of coagulopathy. Researchers suggest that the  abnormal inflammatory response of the host to infection and the cytokine storm may play a crucial role in the endothelial dysfunction that ends up in a hypercoagulability state

Some studies indicate that anticoagulation therapy is associated with a better outcome in COVID-19 septic patients.

While anticoagulation at high doses might become the standard-of-care in the treatment of COVID-19, a new study questions whether that approach will be feasible and safe in all patients. The report in the Journal of Thrombosis & Thrombolysis points out that  the risk of bleeding could be a barrier, especially in older and comorbid patients.

In light of that, Italian researchers from Ospedali Riuniti Marche Nord retrospectively analyzed a cohort of hospitalized COVID-19 patients who received intermediate doses of low molecular weight heparin (LMWH) focusing on feasibility and safety.

Included in the study were 105 hospitalized patients, 61 male and 44 female with a mean age of 73.7. Patients were treated with subcutaneous enoxaparin: 80 mg/day in normal weight and mild-to-moderate impair or normal renal function; 40 mg/day in severe chronic renal failure or low bodyweight (< 45 kg); 100 mg/day was dosed if bodyweight was higher than 100 kg.

Authors note that all the patients had radiologically confirmed pneumonia and 63.8% had severe COVID-19.

Results indicate that none of the patients had fatal hemorrhage, although two (1.9%) patients had a major bleeding event --one spontaneous hematoma and one gastrointestinal bleeding. Only 6.7% of patients needed transfusions of red blood cells. One thrombotic event (pulmonary embolism) was observed.

Researchers advise that, when compared to younger patients, patients older than 85 years had a higher mortality (40% vs 13.3%), but not an increased risk of bleeding or need for blood transfusion.

“The use of an intermediate dose of LWMH appears to be feasible and data suggest safety in COVID-19 patients, although further studies are needed,” the authors conclude.

Go Back

Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing education for the broad spectrum of health care professionals. This site features a searchable database of accredited Power-Pak C.E.® courses on important topics for today's health care professionals.

PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new courses available on the site.